Telix and ITM Join Forces to Create Radiopharma Powerhouse
Filed with ASX · · 36 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Telix Pharmaceuticals
- FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
- FDA Approves Telix Brain Cancer Imaging Drug Pixclara
- Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
- Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
- Telix Appoints David Gill as Chair
Later from Telix Pharmaceuticals
- Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
- FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging
- Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
- Notification of cessation of securities - TLX
- First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals